{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:30:31Z","timestamp":1789504231929,"version":"build-2803163510"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T00:00:00Z","timestamp":1624492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Inflammation might play a critical role in the pathogenesis and progression of Philadelphia-negative myeloproliferative neoplasms (Ph<jats:sup>\u2212<\/jats:sup>MPNs) with elevated inflammatory cytokines in peripheral blood (PB). However, the inflammatory status inside the bone marrow (BM), which is the place of malignancy origin and important microenvironment of neoplasm evolution, has not yet been elucidated.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Inflammatory cytokine profiles in PB and BM of 24 Ph-MPNs patients were measured by a multiplex quantitative inflammation array. Cytokines that correlated between PB and BM were selected and then validated by ELISA in a separate cohort of 52 MPN patients. Furthermore, a panel of cytokines was identified and examined for potential application as non-invasive markers for the diagnosis and prediction of fibrosis progress of MPN subtypes.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> The levels of G-CSF, I-309, IL-1\u03b2, IL-1ra, IL-12p40, IL-15, IL-16, M-CSF, MIG, PDGF-BB, and TIMP-1 in BM supernatants were significantly higher than those in PB (all <jats:italic>p<\/jats:italic> &amp;lt; 0.05). Linear correlations between BM and PB levels were found in 13 cytokines, including BLC, Eotaxin-2, I-309, sICAM-1, IL-15, M-CSF, MIP-1\u03b1, MIP-1\u03b4, RANTES, TIMP-1, TIMP-2, sTNFRI, and sTNFRII (all R &amp;gt; 0.4 and <jats:italic>p<\/jats:italic> &amp;lt; 0.05). Levels of BLC, Eotaxin-2, M-CSF, and TIMP-1 in PB were significantly different from those in health controls (all <jats:italic>p<\/jats:italic> &amp;lt; 0.05). In PB, levels of TIMP-1 and Eotaxin-2 in essential thrombocythemia (ET) group were significantly lower than those in groups of prefibrotic primary myelofibrosis (pre-PMF) [TIMP-1: 685.2 (322.2\u20131,229) ng\/ml vs. 1,369 (1,175\u20131,497) ng\/ml, <jats:italic>p<\/jats:italic> = 0.0221; Eotaxin-2: 531.4 (317.9\u2013756.6) pg\/ml vs. 942.4 (699.3\u20131,474) pg\/ml, <jats:italic>p<\/jats:italic> = 0.0393] and primary myelofibrosis (PMF) [TIMP-1: 685.2 (322.2\u20131229) ng\/ml vs. 1,365 (1,115\u20131,681) ng\/ml, <jats:italic>p<\/jats:italic> = 0.0043; Eotaxin-2: 531.4 (317.9\u2013756.6) pg\/ml vs. 1,010 (818\u20131,556) pg\/ml, <jats:italic>p<\/jats:italic> = 0.0030]. The level of TIMP-1 in myelofibrosis (MF) &amp;gt;1 group was significantly higher than that in MF \u2264 1 group.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Abnormal inflammatory status is present in MPN, especially in its BM microenvironment. Consistency between PB and BM levels was found in multiple inflammatory cytokines. Circulating cytokine levels of BLC, M-CSF, Eotaxin-2, and TIMP-1 reflected inflammation inside BM niche, suggesting potential diagnostic value for MPN subtypes and prognostic value for fibrosis progression.<\/jats:p>","DOI":"10.3389\/fmed.2021.598182","type":"journal-article","created":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T05:36:57Z","timestamp":1624513017000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Cytokine Consistency Between Bone Marrow and Peripheral Blood in Patients With Philadelphia-Negative Myeloproliferative Neoplasms"],"prefix":"10.3389","volume":"8","author":[{"given":"Pu","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boting","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanxia","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luya","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hehui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihui","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanli","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfeng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,6,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood."},{"key":"B2","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.exphem.2014.01.006","article-title":"Cytokine profiles in polycythemia vera and essential thrombocythemia patients: clinical implications","volume":"42","author":"Pourcelot","year":"2014","journal-title":"Exp Hematol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"4005","DOI":"10.1111\/jcmm.13753","article-title":"Increased Dkk-1 plasma levels may discriminate disease subtypes in myeloproliferative neoplasms","volume":"22","author":"Mambet","year":"2018","journal-title":"J Cell Mol Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/j.1365-2141.2005.05674.x","article-title":"Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases","volume":"130","author":"Panteli","year":"2005","journal-title":"Br J Haematol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1186\/s12967-018-1729-7","article-title":"The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms","volume":"16","author":"Greenfield","year":"2018","journal-title":"J Transl Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"3831","DOI":"10.1158\/0008-5472.CAN-10-4002","article-title":"Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor","volume":"71","author":"Manshouri","year":"2011","journal-title":"Cancer Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.stem.2013.06.009","article-title":"Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche","volume":"13","author":"Schepers","year":"2013","journal-title":"Cell Stem Cell."},{"key":"B8","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.tcm.2015.12.001","article-title":"Tissue factor as a link between inflammation and coagulation","volume":"26","author":"Witkowski","year":"2016","journal-title":"Trends Cardiovasc Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"606819","DOI":"10.1155\/2015\/606819","article-title":"Inflammation as a driver of clonal evolution in myeloproliferative neoplasm","volume":"2015","author":"Fleischman","year":"2015","journal-title":"Mediators Inflamm."},{"key":"B10","doi-asserted-by":"publisher","first-page":"5900","DOI":"10.3390\/ijms20235900","article-title":"Diagnostic cytokines and comparative analysis secreted from exfoliated deciduous teeth, dental pulp, and bone marrow derived mesenchymal stem cells for functional cell-based therapy","volume":"20","author":"Yamada","year":"2019","journal-title":"Int J Mol Sci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e0215678","DOI":"10.1371\/journal.pone.0215678","article-title":"Cytokines secreted from bone marrow derived mesenchymal stem cells promote apoptosis and change cell cycle distribution of K562 cell line as clinical agent in cell transplantation","volume":"14","author":"Fathi","year":"2019","journal-title":"PLoS ONE."},{"key":"B12","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.stemcr.2018.05.016","article-title":"ICAM-1 deficiency in the bone marrow niche impairs quiescence and repopulation of hematopoietic stem cells","volume":"11","author":"Liu","year":"2018","journal-title":"Stem Cell Rep."},{"key":"B13","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1182\/blood-2011-11-394775","article-title":"Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?","volume":"119","author":"Hasselbalch","year":"2012","journal-title":"Blood."},{"key":"B14","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/leu.2009.225","article-title":"JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46\/1 haplotype is associated with inferior survival","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia."},{"key":"B15","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.leukres.2012.10.020","article-title":"Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?","volume":"37","author":"Hasselbalch","year":"2013","journal-title":"Leuk Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1038\/leu.2016.12","article-title":"Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both","volume":"30","author":"Koschmieder","year":"2016","journal-title":"Leukemia."},{"key":"B17","doi-asserted-by":"publisher","first-page":"347270","DOI":"10.1155\/2015\/347270","article-title":"The hematopoietic niche in myeloproliferative neoplasms","volume":"2015","author":"Schmitt-Graeff","year":"2015","journal-title":"Mediators Inflamm."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1182\/blood-2016-11-696070","article-title":"The microenvironment in human myeloid malignancies: emerging concepts and therapeutic implications","volume":"129","author":"Medyouf","year":"2017","journal-title":"Blood."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1182\/blood-2009-01-202606","article-title":"The leukemic stem cell niche: current concepts and therapeutic opportunities","volume":"114","author":"Lane","year":"2009","journal-title":"Blood."},{"key":"B20","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1158\/2159-8290.CD-14-0736","article-title":"JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response","volume":"5","author":"Kleppe","year":"2015","journal-title":"Cancer Discov."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1189\/jlb.0113036","article-title":"CXCL13 is elevated in Sjogren's syndrome in mice and humans and is implicated in disease pathogenesis","volume":"94","author":"Kramer","year":"2013","journal-title":"J Leukoc Biol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"632305","DOI":"10.1155\/2015\/632305","article-title":"CXCL13 promotes osteogenic differentiation of mesenchymal stem cells by inhibiting miR-23a expression","volume":"2015","author":"Tian","year":"2015","journal-title":"Stem Cells Int."},{"key":"B23","doi-asserted-by":"publisher","first-page":"3178","DOI":"10.3390\/ijms16023178","article-title":"CXCL13 promotes the effect of bone marrow mesenchymal stem cells (MSCs) on tendon-bone healing in rats and in C3HIOT1\/2 cells","volume":"16","author":"Tian","year":"2015","journal-title":"Int J Mol Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1002\/hep.27328","article-title":"IL-34 and macrophage colony-stimulating factor are overexpressed in hepatitis C virus fibrosis and induce profibrotic macrophages that promote collagen synthesis by hepatic stellate cells","volume":"60","author":"Preisser","year":"2014","journal-title":"Hepatology."},{"key":"B25","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.anai.2009.11.003","article-title":"Eotaxin-2\/CCL24 and eotaxin-3\/CCL26 exert differential profibrogenic effects on human lung fibroblasts","volume":"104","author":"Kohan","year":"2010","journal-title":"Ann Allergy Asthma Immunol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1021\/pr501149m","article-title":"Quantitative proteomics of bronchoalveolar lavage fluid in idiopathic pulmonary fibrosis","volume":"14","author":"Foster","year":"2015","journal-title":"J Proteome Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"109629","DOI":"10.1016\/j.cellsig.2020.109629","article-title":"Exogenous dihydrosphingosine 1 phosphate mediates collagen synthesis in cardiac fibroblasts through JAK\/STAT signalling and regulation of TIMP1","volume":"72","author":"Magaye","year":"2020","journal-title":"Cell Signal."},{"key":"B28","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1080\/17435390.2016.1262919","article-title":"TIMP1 promotes multi-walled carbon nanotube-induced lung fibrosis by stimulating fibroblast activation and proliferation","volume":"11","author":"Dong","year":"2017","journal-title":"Nanotoxicology."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/j.leukres.2006.12.024","article-title":"Global cytokine analysis in myeloproliferative disorders","volume":"31","author":"Ho","year":"2007","journal-title":"Leuk Res."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.598182\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T05:37:01Z","timestamp":1624513021000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.598182\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,24]]},"references-count":29,"alternative-id":["10.3389\/fmed.2021.598182"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.598182","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,24]]},"article-number":"598182"}}